Bulk Pharmaceutical API Sources for PROBUCOL

Bulk Pharmaceutical API Sources for PROBUCOL

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemExper Chemical Directory		YlRPDD@@c`@b`HJHRDbDQBaDaDbDbDRXQDbDbIMAijBhHhJjhBjjh@@@
ChemBlock		ZERO/001429
NovoSeek		4912
MP Biomedicals		156371
MolPort		MolPort-002-042-265
ABI Chem		AC1L1J88

PROBUCOL BULK API SOURCING ANALYSIS

Last updated: February 19, 2026

This report analyzes the current landscape for bulk active pharmaceutical ingredient (API) sourcing for PROBUCOL, a lipid-lowering agent. The analysis focuses on key manufacturers, production capacities, regulatory compliance, and pricing trends relevant to commercial supply.

CURRENT GLOBAL API MANUFACTURING LANDSCAPE

PROBUCOL API manufacturing is concentrated among a limited number of global suppliers, primarily in China and India. These manufacturers operate under varying levels of regulatory oversight, impacting their suitability for different markets.

KEY PRODUCERS AND THEIR GEOGRAPHIC DISTRIBUTION

Major PROBUCOL API manufacturers identified include:

• China: Several entities in China possess the capability to produce PROBUCOL API. Specific company names are proprietary but are known to include large-scale chemical synthesis operations. These facilities often have significant existing capacity for generic APIs.
• India: Indian manufacturers also play a role in PROBUCOL API production. Similar to China, these are typically well-established API producers with existing infrastructure for complex organic synthesis.

PRODUCTION CAPACITY AND SCALE

Production capacity for PROBUCOL API is generally considered sufficient to meet current global demand. Manufacturers can scale production based on demand, with lead times typically ranging from 8 to 16 weeks for large orders. Existing facilities often have multi-purpose synthesis lines, allowing for flexibility in production scheduling. Specific volumetric capacities are not publicly disclosed but are understood to be in the multi-metric ton range annually to support global generic markets.

SUPPLY CHAIN RELIABILITY AND GEOPOLITICAL FACTORS

The reliance on a few key geographic regions for PROBUCOL API production presents potential supply chain risks. Geopolitical tensions, trade disputes, or localized environmental regulations can impact production and export. The COVID-19 pandemic highlighted the vulnerabilities in global API supply chains, leading some pharmaceutical companies to diversify sourcing strategies and explore regional production.

REGULATORY COMPLIANCE AND QUALITY STANDARDS

PROBUCOL API for pharmaceutical formulation must meet stringent quality and regulatory standards to ensure patient safety and product efficacy.

UNITED STATES PHARMACOPEIA (USP) AND EUROPEAN PHARMACOPEIA (EP) COMPLIANCE

API manufacturers must demonstrate compliance with USP and EP monographs for PROBUCOL. This includes specifications for purity, impurity profiles, assay, and physical characteristics. Certification and regular audits by regulatory bodies are essential.

CURRENT GOOD MANUFACTURING PRACTICES (cGMP)

Adherence to cGMP is mandatory for API production intended for regulated markets like the United States, Europe, and Japan. cGMP ensures that APIs are consistently produced and controlled according to quality standards. Manufacturers are subject to inspections by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

DRUG MASTER FILES (DMFs) AND REGULATORY SUBMISSIONS

Manufacturers typically maintain Drug Master Files (DMFs) for PROBUCOL API. These confidential documents are submitted to regulatory authorities and contain detailed information about the manufacturing process, facility, and quality control. Pharmaceutical companies reference these DMFs in their finished drug product applications.

PRICING TRENDS AND COST DRIVERS

The cost of PROBUCOL API is influenced by raw material costs, manufacturing complexity, scale of production, and regulatory compliance burdens.

RAW MATERIAL COSTS

Key raw materials for PROBUCOL synthesis include bisphenol A and sulfur-containing compounds. Fluctuations in the petrochemical market, particularly for bisphenol A, directly impact API production costs. Global commodity pricing for these precursors is a significant cost driver.

MANUFACTURING COMPLEXITY AND YIELD

PROBUCOL synthesis is a multi-step organic process. The efficiency of these steps, including reaction yields and purification processes, directly affects manufacturing costs. Process optimization efforts by manufacturers aim to improve yields and reduce waste.

SCALE OF PRODUCTION AND ECONOMIES OF SCALE

Larger production batches generally result in lower per-unit costs due to economies of scale. Manufacturers with higher throughput and larger synthesis capabilities can offer more competitive pricing.

REGULATORY AND ENVIRONMENTAL COMPLIANCE COSTS

Meeting cGMP standards and environmental regulations adds significant overhead to API manufacturing. Costs associated with quality control, validation, waste management, and regulatory inspections are factored into the API price.

EMERGING MARKET AND FUTURE SUPPLY CHAIN CONSIDERATIONS

The PROBUCOL API market, while mature, faces ongoing shifts in supply chain dynamics and potential future demand drivers.

DIVERSIFICATION OF MANUFACTURING LOCATIONS

To mitigate supply chain risks, there is a growing interest in diversifying API manufacturing beyond traditional hubs. This could involve establishing or contracting with manufacturers in regions such as Eastern Europe or other parts of Asia, though currently, this is not widespread for PROBUCOL.

POTENTIAL FOR NEW SYNTHETIC ROUTES

While established synthetic routes are dominant, research into more efficient or environmentally friendly synthetic pathways for PROBUCOL could emerge. Any breakthroughs that significantly reduce manufacturing costs or improve purity profiles could alter the supplier landscape.

DEMAND FLUCTUATIONS AND MARKET FORECASTS

Demand for PROBUCOL is linked to the prevalence of hyperlipidemia and the use of lipid-lowering therapies. While newer classes of drugs exist, PROBUCOL remains a viable option in certain patient populations and geographies due to its established efficacy and cost-effectiveness. Market forecasts generally indicate stable to moderate demand for generic PROBUCOL.

KEY TAKEAWAYS

• PROBUCOL API manufacturing is concentrated in China and India, with established players possessing significant capacity.
• Regulatory compliance, particularly USP/EP monographs and cGMP, is a critical factor for market access.
• Raw material costs and manufacturing process efficiency are primary drivers of PROBUCOL API pricing.
• Supply chain diversification remains a strategic consideration for pharmaceutical companies due to geopolitical and operational risks.
• Demand for PROBUCOL API is expected to remain stable, supported by its established position in the lipid-lowering market.

FREQUENTLY ASKED QUESTIONS

1. What are the primary regulatory hurdles for importing PROBUCOL API into the United States? The primary regulatory hurdles include the API manufacturer's adherence to Current Good Manufacturing Practices (cGMP) as enforced by the U.S. Food and Drug Administration (FDA), the acceptance of the manufacturer's Drug Master File (DMF) by the FDA, and the API meeting all specifications outlined in the United States Pharmacopeia (USP) monograph for PROBUCOL.

2. How do raw material price fluctuations in petrochemical markets impact the cost of PROBUCOL API? Raw materials like bisphenol A are derived from petrochemical feedstocks. Volatility in crude oil prices and the broader petrochemical market directly influences the cost of these precursors, which in turn increases or decreases the manufacturing cost of PROBUCOL API.

3. What is the typical turnaround time for sourcing a significant quantity (e.g., 1 metric ton) of PROBUCOL API from an established manufacturer? The typical turnaround time for sourcing a significant quantity of PROBUCOL API from an established manufacturer generally ranges from 8 to 16 weeks. This lead time accounts for production scheduling, synthesis, purification, quality control testing, and shipping logistics.

4. Are there any specific environmental regulations in China or India that are currently affecting PROBUCOL API production or export? Both China and India have been progressively implementing stricter environmental regulations. These can affect API production by requiring manufacturers to invest in advanced waste treatment technologies, emission control systems, and potentially leading to temporary shutdowns for non-compliant facilities. Specific impacts on PROBUCOL API production can vary based on the individual manufacturer's compliance status and the localized enforcement of these regulations.

5. What is the minimum purity specification for PROBUCOL API as defined by major pharmacopeias? The minimum purity specification for PROBUCOL API, as defined by major pharmacopeias such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP), typically requires an assay of not less than 98.0% and not more than 102.0% of C28H42O4S2, calculated on the dried basis. Specific impurity limits are also defined.

---

CITATIONS

[1] United States Pharmacopeial Convention. (n.d.). United States Pharmacopeia. Retrieved from [USP Website]

[2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Retrieved from [EDQM Website]

[3] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP) Regulations. Retrieved from [FDA Website]

[4] European Medicines Agency. (n.d.). Good Manufacturing Practice (GMP). Retrieved from [EMA Website]